Ovarian cancer is a malignancy formed by uncontrollable cell growth in the ovarian tissue. It is one of the major gynecological cancers worldwide and a leading cause of cancer death. It is difficult to diagnose ovarian cancer in the initial stages because of the lack of advance diagnostic tools. Moreover, the symptoms of ovarian cancer are similar to that of gastric disorders, which include bloating, abdominal discomfort, and difficulty in eating in the early stages followed by nausea, vomiting, constipation, and diarrhea in the later stages. Ovarian cancer can be treated by using chemotherapy, targeted therapy, and surgery. Though the market has a limited number of drugs for ovarian cancer, late stage pipeline molecules are expected to launch during the forecast period.                                

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Rate of Incidence and Prevalence

08. Market Segmentation by Type of Therapy

08.1.1 Chemotherapy

08.1.2 Targeted Therapy

09. Pipeline Portfolio

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Bristol-Myers Squibb Co.

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Product Segmentation .

19.1.4 Sales by Geography

19.1.5 Business Strategy

19.1.6 Key Information

19.1.7 SWOT Analysis

19.1.8 Strengths

19.1.9 Weaknesses

19.1.10 Opportunities

19.1.11 Threats

19.2 Eli Lilly & Co.

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Business Segmentation by Revenue 2013

19.2.4 Business Segmentation by Revenue 2012 and 2013

19.2.5 Sales by Geography

19.2.6 Business Strategy

19.2.7 Key Developments

19.2.8 SWOT Analysis

19.2.9 Strengths

19.2.10 Weaknesses

19.2.11 Opportunities

19.2.12 Threats

19.3 GlaxoSmithKline plc

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Business Segmentation

19.3.4 Business Segmentation by Revenue 2012 and 2013

19.3.5 Sales by Geography

19.3.6 Pipeline Products

19.3.7 Business Strategy

19.3.8 Key Information

19.3.9 SWOT Analysis

19.3.10 Strengths

19.3.11 Weaknesses

19.3.12 Opportunities

19.3.13 Threats

19.4 Janssen Pharmaceuticals Inc.

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Business Segmentation

19.4.4 Business Strategy

19.4.5 Key Developments

19.4.6 SWOT Analysis

19.4.7 Strengths

19.4.8 Weaknesses

19.4.9 Opportunities

19.4.10 Threats

19.5 F. Hoffmann-La Roche Ltd.

19.5.1 Key Facts

19.5.2 Business Overview

19.5.3 Business Segmentation

19.5.4 Business Strategy

19.5.5 Sales Segmentation by Business

19.5.6 Geographical Sales Segmentation by Business Segment

19.5.7 Key Information

19.5.8 SWOT Analysis

19.5.9 Strengths

19.5.10 Weaknesses

19.5.11 Opportunities

19.5.12 Threats

20. Other Reports in this Series